Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMCR Stock Forecast 2026-2027
$33.78
Current Price
$1.72B
Market Cap
Buy 10
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to IMCR Price Targets
+196.0%
To High Target of $100.00
+80.6%
To Median Target of $61.00
+0.7%
To Low Target of $34.00
IMCR Price Momentum
+3.9%
1 Week Change
+18.4%
1 Month Change
-2.3%
1 Year Change
-2.7%
Year-to-Date Change
-17.0%
From 52W High of $40.72
+22.6%
From 52W Low of $27.56
📊 TOP ANALYST CALLS
Did IMCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Immunocore is one of their latest high-conviction picks.
Latest IMCR Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, IMCR has a bullish consensus with a median price target of $61.00 (ranging from $34.00 to $100.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $33.78, the median forecast implies a 80.6% upside. This outlook is supported by 10 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 196.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMCR Analyst Ratings
10
Buy
4
Hold
0
Sell
IMCR Price Target Range
Low
$34.00
Average
$61.00
High
$100.00
Current: $33.78
Latest IMCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 20, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $100.00 |
| Apr 14, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $100.00 |
| Mar 16, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| Feb 26, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 4, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $55.00 |
| Nov 10, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 31, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Oct 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 18, 2025 | Guggenheim | Paul Jeng | Neutral | Assumes | $N/A |
| Jun 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 8, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 14, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Apr 10, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 7, 2025 | Mizuho | Neutral | Maintains | $N/A | |
| Mar 12, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 12, 2025 | Needham | Buy | Reiterates | $N/A | |
| Mar 7, 2025 | Morgan Stanley | Andrew Galler | Equal-Weight | Assumes | $35.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Immunocore Holdings plc American Depositary Receipt (IMCR) Competitors
The following stocks are similar to Immunocore based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IMCR
Immunocore
mkt cap
1.65B
Immunocore Holdings plc American Depositary Receipt (IMCR) Financial Data
Immunocore Holdings plc American Depositary Receipt has a market capitalization of $1.72B with a P/E ratio of -47.6x. The company generates $412.81M in trailing twelve-month revenue with a -6.7% profit margin.
Revenue growth is +13.6% quarter-over-quarter, while maintaining an operating margin of +6.8% and return on equity of -7.1%.
Valuation Metrics
Market Cap
$1.72B
Enterprise Value
$1.29B
P/E Ratio
-47.6x
PEG Ratio
-0.3x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
+13.6%
Gross Margin
+99.6%
Operating Margin
+6.8%
Net Margin
-6.7%
EPS Growth
+158.2%
Financial Health
Cash/Price Ratio
+49.2%
Current Ratio
4.2x
Debt/Equity
110.7x
ROE
-7.1%
ROA
-0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Immunocore Holdings plc American Depositary Receipt (IMCR) Business Model
About Immunocore Holdings plc American Depositary Receipt
What They Do
Develops innovative T cell receptor therapies.
Business Model
Immunocore Holdings plc generates revenue through the development and commercialization of T cell receptor (TCR) therapies aimed at treating cancer, autoimmune disorders, and infectious diseases. By pioneering ImmTAC technology, the company targets cancerous cells, creating potential licensing and partnership opportunities within the biotechnology sector.
Additional Information
As an American Depository Receipt (ADR), Immunocore allows US investors to engage with this UK-based company without the complexities of foreign market investments. The company is recognized for its significant contributions to immunotherapy, addressing critical medical challenges and holding substantial growth potential in a rapidly evolving industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
497
CEO
Dr. Bahija Jallal Ph.D.
Country
United Kingdom
IPO Year
2021
Website
www.immunocore.comImmunocore Holdings plc American Depositary Receipt (IMCR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Jul 07, 2026
By Zacks Equity Research
Analyst Blog
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.
Jul 07, 2026
By Zacks Equity Research
Analyst Blog
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
Jul 06, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Immunocore has evolved into a self-funded platform with strong sales from KIMMTRAK. Upcoming catalysts include pivotal data for tebentafusp and brenetafusp and expansion of its PRAME franchise.
Why It Matters
Immunocore's transition to a self-funded platform with strong sales positions it well for growth, reducing reliance on equity dilution and enhancing its pipeline potential through upcoming catalysts.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
IMCR reports strong sales growth for Kimmtrak and is pursuing label expansion studies to enhance its melanoma treatment options.
Why It Matters
Strong Kimmtrak sales growth and potential label expansion indicate increased revenue opportunities for IMCR, potentially boosting its stock value and market position in melanoma treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
4 Biotech Stocks Investors Should Watch in 2026
1 month ago
Quick Summary
New drug approvals and positive pipeline developments support growth in the Zacks Biomedical and Genetics industry. Companies LQDA, IMNM, STOK, and IMCR are well-positioned despite market uncertainty.
Why It Matters
New drug approvals and pipeline advancements signal growth potential for LQDA, IMNM, STOK, and IMCR, offering opportunities in a challenging economic climate.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immunocore's brenetafusp shows an 87% 6-month survival rate and 52% disease control in advanced melanoma. The 160 mcg dose is selected for Phase 3 trials, with favorable tolerability noted.
Why It Matters
Positive Phase 1 results for brenetafusp indicate strong survival rates in advanced melanoma, enhancing its potential value and attractiveness for investors in biotech and oncology sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
1 month ago
Quick Summary
Wall Street analysts' average price target for Immunocore (IMCR) suggests a potential upside of 111.5%, supported by positive earnings estimate revisions.
Why It Matters
The 111.5% upside potential in Immunocore's price targets signals strong investor interest, while positive earnings revisions suggest improved company performance, potentially boosting stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immunocore's Q1 net sales for KIMMTRAK reached $106.7 million, a 14% year-over-year increase. The company reported $845 million in cash and marketable securities as of March 31, 2026.
Why It Matters
Immunocore's strong sales growth and promising clinical results for KIMMTRAK indicate robust demand and potential for future revenue, bolstering investor confidence in the company's financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IMCR Stock
What is Immunocore Holdings plc American Depositary Receipt's (IMCR) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Immunocore Holdings plc American Depositary Receipt (IMCR) has a median price target of $61.00. The highest price target is $100.00 and the lowest is $34.00.
Is IMCR stock a good investment in 2027?
According to current analyst ratings, IMCR has 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMCR stock?
Wall Street analysts predict IMCR stock could reach $61.00 in the next 12 months. This represents a 80.6% increase from the current price of $33.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immunocore Holdings plc American Depositary Receipt's business model?
Immunocore Holdings plc generates revenue through the development and commercialization of T cell receptor (TCR) therapies aimed at treating cancer, autoimmune disorders, and infectious diseases. By pioneering ImmTAC technology, the company targets cancerous cells, creating potential licensing and partnership opportunities within the biotechnology sector.
What is the highest forecasted price for IMCR Immunocore Holdings plc American Depositary Receipt?
The highest price target for IMCR is $100.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 196.0% increase from the current price of $33.78.
What is the lowest forecasted price for IMCR Immunocore Holdings plc American Depositary Receipt?
The lowest price target for IMCR is $34.00 from at , which represents a 0.7% increase from the current price of $33.78.
What is the overall IMCR consensus from analysts for Immunocore Holdings plc American Depositary Receipt?
The overall analyst consensus for IMCR is bullish. Out of 6 Wall Street analysts, 10 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $61.00.
How accurate are IMCR stock price projections?
Stock price projections, including those for Immunocore Holdings plc American Depositary Receipt, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 6:45 AM UTC